

# H Joachim Deeg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4515008/publications.pdf>

Version: 2024-02-01

106  
papers

8,081  
citations

61945

43  
h-index

48277

88  
g-index

107  
all docs

107  
docs citations

107  
times ranked

6809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stable Mixed Hematopoietic Chimerism in DLA-Identical Littermate Dogs Given Sublethal Total Body Irradiation Before and Pharmacological Immunosuppression After Marrow Transplantation. <i>Blood</i> , 1997, 89, 3048-3054.	0.6	584
2	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017, 35, 1154-1161.	0.8	495
3	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. <i>Cancer Cell</i> , 2015, 27, 617-630.	7.7	449
4	Comorbidity and Disease Statusâ€‘Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4246-4254.	0.8	380
5	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	0.8	361
6	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	0.8	321
7	Hematopoietic cell transplantationâ€‘specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	0.6	292
8	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). <i>Leukemia Research</i> , 2007, 31, 737-740.	0.4	288
9	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 1273-1283.	0.8	281
10	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
11	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
12	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826.	0.6	190
13	Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 355-365.	2.0	174
14	BONE MARROW TRANSPLANTATION: A REVIEW OF DELAYED COMPLICATIONS. <i>British Journal of Haematology</i> , 1984, 57, 185-208.	1.2	160
15	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€‘2007 Versus 2013â€‘2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	2.0	157
16	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , 2015, 125, 3347-3350.	0.6	152
17	Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. <i>Blood</i> , 2012, 120, 1398-1408.	0.6	148
18	Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 320-327.	2.0	142

#	ARTICLE	IF	CITATIONS
19	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2657-2664.	0.6	133
20	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996.	0.6	122
21	Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 2000, 37, 405-414.	0.6	121
22	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 908-915.	2.0	113
23	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	3.3	97
24	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989, 72, 567-572.	1.2	95
25	Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 341-350.	2.0	95
26	Who is fit for allogeneic transplantation?. <i>Blood</i> , 2010, 116, 4762-4770.	0.6	93
27	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 573-584.	2.0	88
28	Age-dependent cyclosporine: Pharmacokinetics in marrow transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 438-443.	2.3	86
29	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	0.6	83
30	Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2134-2141.	0.8	79
31	Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. <i>British Journal of Haematology</i> , 1987, 66, 115-121.	1.2	76
32	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
33	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 713-720.	2.0	70
34	Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft-versus-host disease. <i>Medical and Pediatric Oncology</i> , 1985, 13, 165-172.	1.0	69
35	Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1033-1039.	2.0	65
36	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1 dose de-escalation study. <i>Lancet Haematology</i> , 2015, 2, e367-e375.	2.2	64

#	ARTICLE	IF	CITATIONS
37	Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for $\lt;i>TP53</i>$ -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2022, 40, 3985-3993.	0.8	62
38	Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 265-272.	2.0	59
39	$\hat{\pm}$ -1-Antitrypsin (AAT) $\hat{\epsilon}$ “modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. <i>Blood</i> , 2014, 124, 2881-2891.	0.6	54
40	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
41	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes $\hat{\epsilon}$ ”Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 483.e1-483.e6.	0.6	52
42	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60 $\hat{\epsilon}$ ”78 $\hat{\epsilon}$ years of age. <i>British Journal of Haematology</i> , 2011, 153, 76-82.	1.2	51
43	Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1996-2003.	2.0	51
44	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. <i>British Journal of Haematology</i> , 1996, 92, 699-706.	1.2	48
45	Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1669-1677.	2.0	45
46	The canine major histocompatibility complex. <i>Tissue Antigens</i> , 1983, 21, 360-373.	1.0	41
47	Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. <i>British Journal of Haematology</i> , 2001, 114, 944-950.	1.2	40
48	Regression of Myelofibrosis and Osteosclerosis following Hematopoietic Cell Transplantation Assessed by Magnetic Resonance Imaging and Histologic Grading. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1285-1294.	2.0	40
49	Myelodysplastic Syndromes, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 261-272.	2.3	40
50	Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. <i>British Journal of Haematology</i> , 2000, 110, 217-222.	1.2	39
51	Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 176-179.	2.0	39
52	Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). <i>British Journal of Haematology</i> , 1993, 84, 515-520.	1.2	36
53	Hematopoietic Cell Transplantation as Curative Therapy for $\hat{A}$ Patients with Myelofibrosis: Long-Term Success in all Age $\hat{A}$ Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1883-1887.	2.0	36
54	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1227-1233.	2.0	36

#	ARTICLE	IF	CITATIONS
55	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021, 35, 2445-2459.	3.3	36
56	Marrow transplantation in hepatitis-associated aplastic anemia. <i>American Journal of Hematology</i> , 1984, 17, 269-278.	2.0	35
57	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1509-1514.	2.0	33
58	Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 613-620.	2.0	31
59	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 373-378.	2.0	30
60	Uncertainty of Physicians and Patients in Medical Decision Making. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 865-869.	2.0	30
61	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL <sup>-</sup> negative MPN in blast phase. <i>Blood Advances</i> , 2020, 4, 5562-5573.	2.5	28
62	The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy. <i>PLoS ONE</i> , 2014, 9, e107817.	1.1	27
63	Acute-Phase Protein Î±1-Antitrypsin <sup>+</sup> A Novel Regulator of Angiopoietin-like Protein 4 Transcription and Secretion. <i>Journal of Immunology</i> , 2014, 192, 5354-5362.	0.4	26
64	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	2.5	25
65	Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. <i>Haematologica</i> , 2020, 105, 652-660.	1.7	23
66	Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1446-1454.	2.0	22
67	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	3.3	22
68	Murine xenogeneic models of myelodysplastic syndrome: An essential role for stroma cells. <i>Experimental Hematology</i> , 2014, 42, 4-10.	0.2	20
69	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
70	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 263-272.	1.1	17
71	Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes. <i>Haematologica</i> , 2017, 102, e216-e218.	1.7	16
72	Angioimmunoblastic lymphadenopathy with retinitis and drug related exacerbations. A clinicopathological case study. <i>Cancer</i> , 1979, 44, 1745-1750.	2.0	13

#	ARTICLE	IF	CITATIONS
73	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e375-e380.	1.8	13
74	Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?. Biology of Blood and Marrow Transplantation, 2018, 24, 649-658.	2.0	13
75	Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. Biology of Blood and Marrow Transplantation, 2020, 26, 2197-2203.	2.0	12
76	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. Blood Advances, 2020, 4, 3302-3310.	2.5	11
77	Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics. JAMA Oncology, 2015, 1, 571.	3.4	9
78	Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1371-1374.	2.0	9
79	Quantitative analysis of glycans, related genes, and proteins in two human bone marrow stromal cell lines using an integrated strategy. Experimental Hematology, 2015, 43, 760-769.e7.	0.2	7
80	Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease. Hematology/Oncology Clinics of North America, 2014, 28, 1023-1035.	0.9	6
81	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 390-395.	0.2	6
82	Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation. Blood Advances, 2022, 6, 1623-1627.	2.5	6
83	Renal Cyclosporine Clearance in Marrow Transplant Recipients: Age-Related Variation. Journal of Clinical Pharmacology, 1986, 26, 658-661.	1.0	5
84	Allogeneic Hematopoietic Cell Transplantation and Other Expensive Cellular Therapies: A Miracle for the Few but Off Limits to Many?. Journal of Clinical Oncology, 2020, 38, 1268-1272.	0.8	5
85	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation. , 0, , 1620-1637.		4
86	New Somatic Mutation in the PIG-A Gene Emerges at Relapse of Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 3422-3427.	0.6	4
87	Chimerism, the Microenvironment and Control of Leukemia. Frontiers in Immunology, 2021, 12, 652105.	2.2	3
88	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Blood, 2012, 120, 4164-4164.	0.6	3
89	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. Blood, 1997, 89, 3880-3887.	0.6	3
90	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders. , 0, , 827-844.		2

#	ARTICLE	IF	CITATIONS
91	Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. <i>British Journal of Haematology</i> , 1987, 66, 115-121.	1.2	2
92	Donor Treatment with $\pm 1$ Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects. <i>Blood</i> , 2012, 120, 1889-1889.	0.6	2
93	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	2
94	Choosing a Regimen for Prophylaxis of Graft-versus-Host Disease. <i>BioDrugs</i> , 1997, 7, 15-22.	2.2	1
95	Disruption of Iron Regulation after Radiation and Donor Cell Infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1173-1181.	2.0	1
96	JAK Inhibitors Prior to Allogeneic Stem Cell Transplant for Patients with Myelofibrosis: A Prospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S39.	2.0	1
97	More than one angle to target aplastic anemia?. <i>Cancer</i> , 2018, 124, 4165-4167.	2.0	1
98	Individuals, Boundaries, and Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e309-e312.	2.0	1
99	A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2013, 122, 3926-3926.	0.6	1
100	The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep. <i>Blood</i> , 2013, 122, 1543-1543.	0.6	1
101	Genetics, prognosis, and transplantation for myelofibrosis. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e24.	0.6	0
102	Asymmetric dimethylarginine “a prognostic marker for transplant outcome?. <i>Haematologica</i> , 2019, 104, 646-647.	1.7	0
103	Transferrin (Tf) Mediated Protection of the Liver Against Fas-Induced Injury Requires Tf-Receptor Type 2 and Is Modulated by Baseline Plasma Iron Levels.. <i>Blood</i> , 2006, 108, 1557-1557.	0.6	0
104	Impact of Pretransplant Neutropenia on Post-Transplant Outcome in Patients with Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2006, 108, 599-599.	0.6	0
105	Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis. <i>Blood</i> , 2013, 122, 712-712.	0.6	0
106	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 1317-1317.	0.6	0